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LIBERATING CLINICAL TRIAL DATA
Benefits of, and barriers to, reactivating dormant trials
Ruth Gilbert professor of clinical epidemiology 1, Katie Harron research fellow in statistics 2, Lorraine
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1UCL Institute of Child Health, LondonWC1N 1EH, UK; 2London School of Hygiene and Tropical Medicine, London, UK; 3UCL Institute of Education,
London, UK
The UK should follow Ontario and reactivate its treasure trove
of dormant trials to generate new science through linkage with
administrative data.1Many groups stand to benefit. For example,
drug regulators could encourage linkage of dormant and new
trials to administrative data to monitor long term safety of
drugs.2 Linkage would also lead to better evidence on the long
term effects of interventions in early life. For example, trials in
the 1980s and 1990s led to early enriched nutrition for preterm
babies worldwide, but uncertainty about whether cognitive
benefits outweigh cardiovascular harms can be resolved only
through linkage to administrative data in adolescence and
adulthood from health, education, and employment sectors.3 4
So what are the barriers to reactivating dormant trials in the
UK? Firstly, cost. Access to primary care data on 10% of the
population held in the Clinical Practice Research Datalink costs
six figure sums each year. Few researchers, apart from those in
the commercial sector, can afford the data. Second is capacity.
Hospital data for England are more affordable than data from
primary care but the Health and Social Care Information Centre
currently has a backlog of more than 200 applications.5 Each
week it receives more applications than it processes.
The third barrier is the requirement for consent to link data to
dormant trials. Trials from the 1980s and 1990s did not ask for
consent to link to administrative data 30 years later. But rules
to safeguard privacy might prevent benefits for society.6Ontario
is reviewing its policies to make better use of past investments
by trial participants and research funders. The UK should do
the same. Connecting rigorous science to data from public
services will reap benefits far beyond the original trial questions.
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